Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 and Atezolizumab in Previously Untreated Advanced NSCLC
NCT04984811Phase 2Terminated
- Sponsor
- NeoImmuneTech
- Start
- Nov 2021
- Primary completion
- Aug 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efineptakin alfa in non-small cell lung cancer (NSCLC), sponsored by NeoImmuneTech. Primary endpoint: Objective Response Rate up to 2 years. Started Nov 2021; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04984811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984811.